Please login to the form below
AZD3293
This page shows the latest AZD3293 news and features for those working in and with pharma, biotech and healthcare.
Off BACE: AZ/Lilly drop Alzheimer’s drug lanabecestat
The demise of the BACE1 inhibitor – also known as AZD3293/LY3314814 – adds to the litany of failures among drugs intended to treat Alzheimer’s, and specifically those trying to slow down
Latest news
-
Biogen rises on more positive data for Alzheimer's candidate
compounds. . Last week, it partnered with AstraZeneca (AZ) on MEDI1814, an antibody against amyloid-beta 42 (Aβ42) in phase I trials, and is also working with AZ on BACE inhibitor AZD3293,
-
Lilly taps AstraZeneca for another anti-amyloid drug
The two companies are already working together on AZD3293, a BACE inhibitor which is designed to interrupt the formation of Aβ at an early stage in the process, and are running
-
Lilly sinks as solanezumab fails again in Alzheimer's
AZD3293. Ricks has previously suggested that if EXPEDITION3 was a bust then the expensive, 2, 500-patient prodromal trial will probably be abandoned.
-
AZ-Lilly start second pivotal trial of fast-tracked Alzheimer's drug
AMARANTH could be first treatment to target underlying mechanism. . AstraZeneca and Eli Lilly's collaboration in Alzheimer's disease continues to make progress, as their AZD3293 drug is granted a ... AZ and Lilly are already carrying out one phase
-
Eisai and Biogen plan phase III trials for Alzheimer's drug
others. Merck has already started phase III trials of its MK-8931 candidate, while Lilly and AZ recently did likewise with AZD3293.
More from news
Approximately 1 fully matching, plus 12 partially matching documents found.
Latest Intelligence
-
Deal Watch October 2016
Lilly. AZD3293. $500 profit share. Neurology 2012. Impax US. Zomig US.
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Sales Director, Healthcare communications agency, London/ SE UK
-
Six figure salary
- Senior Account Director - Med Comms Agency
-
Salary TBC
- ACCOUNT MANAGER / SENIOR ACCOUNT MANAGER
-
Salary TBC
-
MEDICAL WRITER - HOME WORKING
-
Salary TBC
-
SENIOR MEDICAL WRITER
-
Salary TBC
- Sinovac’s COVID-19 vaccine appears safe in older adults
- Bayer’s finerenone scores FDA priority review for chronic kidney disease
- FDA authorises flexible storage for Pfizer/BioNTech COVID-19 vaccine
- AZ/Oxford University vaccine shows 82.4% efficacy with extended dosing schedule
- Pfizer/BioNTech vaccine is 94% effective after second dose, major real-world study finds
- FDA considers new safety warnings for Pfizer’s JAK inhibitor Xeljanz
- Live Webinar: There's No Going Back: How COVID-19 will Change Pharma Forever
- Live Webinar: Leading Successful Change Through Innovative Digital Technologies
- Living with psoriasis: a patient perspective
- UK study finds Pfizer/BioNTech, AZ/Oxford vaccines reduce severe COVID-19 in older people
- The imperfect art of sustainable communications
- AZ sells stake in Moderna for around $1.2bn
PMHub
BOLDSCIENCE
We know what it takes to create brands, to start new conversations, to simply communicate complex science, to change lives…...
Latest intelligence
- Good design saves lives
- Good design and creative thinking are essential if we are to improve on existing problems in new ways, which is why design and creativity within healthcare is vital. Health is...
- Why you must understand the pricing of patient recruitment companies
- Recruiting a diverse range of patients and engaging with them for your clinical trial isn’t an easy task, which means you might turn to patient recruitment companies, like us, who...
- A cultural shift in clinical research
- Research organisations across the board are experimenting with new technologies...
Quick links
Infographics
